Valion Bio, Inc. Business Acquisition, Transaction Costs
Valion Bio, Inc. (VBIO) had Business Acquisition, Transaction Costs of $243.00 thousand as of 2025-02-11, per its 10-Q filed 2025-08-14.
Financial Statements › Notes
us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts · last filed 2025-08-14
- 2025-02-11: Business Acquisition, Transaction Costs $243.00K; Business Acquisition, Transaction Costs as first filed $226.00K.
| Period end | Business Acquisition, Transaction Costs | Business Acquisition, Transaction Costs as first filed |
|---|---|---|
| 2025-02-11 | $243.00K 10-Q · filed 2025-08-14 | $226.00K 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |